secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001641172-25-024088
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Q1 revenue $40.2M, up 114% YoY; operating profit $21.7M, up 462%
----------------------------------------------------------------------

- Consolidated revenues of $40.2M for Q1 FY2026, a 114% increase YoY from the prior year comparable period.
- Operating profits of $21.7M, a 462% increase YoY, driven by sales of lisdexamfetamine products and strong Elite label growth.
- Lisdexamfetamine products launched after the prior year Q1, contributing significantly to the top-line expansion.
- Company will host a conference call on August 15, 2025 at 11:30 AM EDT to discuss results and provide a business update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000164117225024088/0001641172-25-024088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000164117225024088/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-024088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer